Hsbc Holdings PLC Purchases 23,147 Shares of Sarepta Therapeutics, Inc. $SRPT

Key Points

• Hsbc Holdings PLC increased its holdings in Sarepta Therapeutics by 28.7% during the first quarter, owning approximately 0.11% of the company's stock valued at $6.6 million.
• Sarepta's earnings report showed a 68.4% year-over-year revenue increase, with an EPS of $2.02, surpassing analyst expectations by $1.13.
• Analysts have set varied price targets for Sarepta, with a consensus average of $43.50, while eight analysts rated it a "Buy."

Hsbc Holdings PLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 28.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 103,700 shares of the biotechnology company's stock after buying an additional 23,147 shares during the quarter. Hsbc Holdings PLC owned approximately 0.11% of Sarepta Therapeutics worth $6,618,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the company. Farallon Capital Management LLC lifted its holdings in shares of Sarepta Therapeutics by 11.1% during the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company's stock valued at $348,368,000 after buying an additional 285,100 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Sarepta Therapeutics by 27.9% during the 1st quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company's stock valued at $168,907,000 after buying an additional 577,848 shares during the last quarter. Alkeon Capital Management LLC lifted its holdings in shares of Sarepta Therapeutics by 34.7% during the 4th quarter. Alkeon Capital Management LLC now owns 853,845 shares of the biotechnology company's stock valued at $103,819,000 after buying an additional 220,000 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Sarepta Therapeutics by 22.6% during the 4th quarter. Northern Trust Corp now owns 803,511 shares of the biotechnology company's stock valued at $97,699,000 after buying an additional 147,874 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Sarepta Therapeutics by 438.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company's stock valued at $45,477,000 after buying an additional 580,123 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. BMO Capital Markets lifted their price target on Sarepta Therapeutics from $25.00 to $50.00 and gave the company a "market perform" rating in a report on Tuesday, July 29th. Robert W. Baird raised their price objective on Sarepta Therapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Leerink Partnrs downgraded Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, July 18th. UBS Group reissued a "neutral" rating on shares of Sarepta Therapeutics in a research note on Monday, July 21st. Finally, Wolfe Research initiated coverage on Sarepta Therapeutics in a research note on Tuesday, June 17th. They issued a "peer perform" rating on the stock. Eight research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have issued a Sell rating to the stock. According to MarketBeat.com, Sarepta Therapeutics has a consensus rating of "Hold" and an average price target of $43.50.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT traded up $0.27 during trading on Thursday, hitting $18.34. The company's stock had a trading volume of 5,495,896 shares, compared to its average volume of 10,498,255. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84. The firm has a 50 day moving average price of $17.76 and a 200 day moving average price of $48.09. The firm has a market cap of $1.79 billion, a P/E ratio of -21.08 and a beta of 0.46. Sarepta Therapeutics, Inc. has a 52 week low of $10.41 and a 52 week high of $140.10.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, topping the consensus estimate of $0.89 by $1.13. The company had revenue of $611.09 million for the quarter, compared to the consensus estimate of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The company's revenue for the quarter was up 68.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.07 EPS. Equities research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.